200 related articles for article (PubMed ID: 12169865)
1. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
Iida N; Koshikawa S; Akizawa T; Tsubakihara Y; Marumo F; Akiba T; Kawaguchi Y; Imada A; Yamazaki C; Suzuki M
Am J Nephrol; 2002; 22(4):338-46. PubMed ID: 12169865
[TBL] [Abstract][Full Text] [Related]
2. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
[TBL] [Abstract][Full Text] [Related]
3. Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
Akizawa T; Koshikawa S; Iida N; Marumo F; Akiba T; Kawaguchi Y; Imada A; Yamazaki C; Suzuki M; Tubakihara Y
Nephron; 2002 Apr; 90(4):384-90. PubMed ID: 11961396
[TBL] [Abstract][Full Text] [Related]
4. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
Kaufmann H; Saadia D; Voustianiouk A; Goldstein DS; Holmes C; Yahr MD; Nardin R; Freeman R
Circulation; 2003 Aug; 108(6):724-8. PubMed ID: 12885750
[TBL] [Abstract][Full Text] [Related]
5. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
Freeman R; Landsberg L; Young J
Neurology; 1999 Dec; 53(9):2151-7. PubMed ID: 10599797
[TBL] [Abstract][Full Text] [Related]
6. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
Kaufmann H
Clin Auton Res; 2008 Mar; 18 Suppl 1():19-24. PubMed ID: 18368303
[TBL] [Abstract][Full Text] [Related]
7. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
Lamotte G; Holmes C; Sullivan P; Goldstein DS
Clin Auton Res; 2019 Feb; 29(1):113-117. PubMed ID: 30229336
[TBL] [Abstract][Full Text] [Related]
8. Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension.
Fujisaki K; Kanai H; Hirakata H; Nakamura S; Koga Y; Hattori F; Iida M
Ther Apher Dial; 2007 Feb; 11(1):49-55. PubMed ID: 17309575
[TBL] [Abstract][Full Text] [Related]
9. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
Hoeldtke RD; Cilmi KM; Mattis-Graves K
Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398
[TBL] [Abstract][Full Text] [Related]
10. Treatment of dialysis-induced hypotension with L-threo-3,4-dihydroxyphenylserine.
Iida N; Tsubakihara Y; Shirai D; Imada A; Suzuki M
Nephrol Dial Transplant; 1994; 9(8):1130-5. PubMed ID: 7800213
[TBL] [Abstract][Full Text] [Related]
11. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
Sakoda S; Suzuki T; Higa S; Ueji M; Kishimoto S; Matsumoto M; Yoneda S
Eur Neurol; 1985; 24(5):330-4. PubMed ID: 3932074
[TBL] [Abstract][Full Text] [Related]
12. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.
Man in 't Veld AJ; Boomsma F; van den Meiracker AH; Julien C; Lenders J; Schalekamp MA
J Hypertens Suppl; 1988 Dec; 6(4):S547-9. PubMed ID: 3149290
[TBL] [Abstract][Full Text] [Related]
13. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
Birkmayer W; Birkmayer G; Lechner H; Riederer P
J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure.
Goldstein DS; Holmes C; Kaufmann H; Freeman R
Clin Auton Res; 2004 Dec; 14(6):363-8. PubMed ID: 15666063
[TBL] [Abstract][Full Text] [Related]
15. Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine.
Carvalho MJ; van den Meiracker AH; Boomsma F; Man in 't Veld AJ; Freitas J; Costa O; de Freitas AF
J Auton Nerv Syst; 1997 Jan; 62(1-2):63-71. PubMed ID: 9021651
[TBL] [Abstract][Full Text] [Related]
16. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
Kaufmann H; Freeman R; Biaggioni I; Low P; Pedder S; Hewitt LA; Mauney J; Feirtag M; Mathias CJ;
Neurology; 2014 Jul; 83(4):328-35. PubMed ID: 24944260
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation and long-term follow-up of dopamine beta hydroxylase deficiency.
Wassenberg T; Deinum J; van Ittersum FJ; Kamsteeg EJ; Pennings M; Verbeek MM; Wevers RA; van Albada ME; Kema IP; Versmissen J; van den Meiracker T; Lenders JWM; Monnens L; Willemsen MA
J Inherit Metab Dis; 2021 May; 44(3):554-565. PubMed ID: 33034372
[TBL] [Abstract][Full Text] [Related]
18. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
Mathias CJ
Clin Auton Res; 2008 Mar; 18 Suppl 1():25-9. PubMed ID: 18368304
[TBL] [Abstract][Full Text] [Related]
19. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency.
Man in 't Veld AJ; Boomsma F; van den Meiracker AH; Schalekamp MA
Lancet; 1987 Nov; 2(8569):1172-5. PubMed ID: 2890807
[TBL] [Abstract][Full Text] [Related]
20. The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance.
Tanaka H; Yamaguchi H; Mino M
Clin Auton Res; 1996 Aug; 6(4):189-93. PubMed ID: 8902314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
